BPC-157 as an Emerging Supportive Therapy
Samuel Sarmiento MD, MPH, MBA
BPC-157 as an Emerging Supportive Therapy in Viral Illnesses
by Dr. James Ross
BPC-157 and Its Relevance in COVID-19 Management
The outbreak of coronavirus disease (COVID-19) in late 2019 has developed into a widespread global health crisis. COVID-19 is increasingly recognized as not only a respiratory illness but also a vascular and thrombotic disorder that targets endothelial cells (ECs). The resulting endothelial dysfunction contributes to multi-organ complications such as acute respiratory distress syndrome (ARDS), cardiovascular injury, hepatic impairment, and neurological sequelae.
BPC-157, a research compound available through licensed peptides, has demonstrated endothelial-protective, anti-inflammatory, and cytoprotective properties in preclinical models. Through activation of endothelial nitric oxide synthase (eNOS), BPC-157 supports nitric oxide (NO) release, vascular repair, and angiogenic modulation. These mechanisms may reduce inflammation, stabilize vascular function, and mitigate the severity of disease progression. While human studies remain limited, its potential as a complementary therapy for COVID-19 warrants further investigation.
Mechanistic Insight: eNOS and Nitric Oxide Pathways
Severe COVID-19 cases are often marked by loss of eNOS activity or dysfunctional regulation of nitric oxide signaling, leading to vascular instability, hypertension, and thrombosis. Deficiency of NO is strongly linked with vascular injury and clot formation, both common in critical COVID-19 presentations.
In animal models, BPC-157 has been shown to positively regulate eNOS activity and restore NO balance. It counteracts the inhibitory effects of L-NAME and modulates vasomotor tone through NO-dependent pathways, particularly the Src-Cav-1-eNOS axis. These findings suggest that BPC-157 may reduce viral burden and limit endothelial-platelet dysfunction if applied in early intervention settings.
Cardiovascular Protection Observed in Preclinical Studies
BPC-157 has demonstrated cardioprotective actions in multiple animal studies, including:
Prevention and resolution of inferior vena cava hypertension
Reduction of arrhythmia duration during hypoxia-reoxygenation injury
Attenuation of right heart failure induced by acute thrombotic coronary occlusion
Protection against pulmonary interstitial edema
Reduction of lymphocyte depletion, vascular congestion, and lung injury
These outcomes mirror the cardiovascular complications associated with severe COVID-19, such as coagulopathy, myocardial damage, arrhythmias, and pulmonary embolism. The data suggest potential use in attenuating cardiovascular and thromboembolic disturbances seen in viral illness progression.
Hepatic and Pulmonary Modulation
Hepatic dysfunction is a frequent complication among hospitalized COVID-19 patients. Preclinical findings demonstrate that BPC-157 can:
Improve outcomes in models of liver injury, including bile duct ligation and hepatic encephalopathy
Normalize arterial and portal pressures, reduce thrombotic activity, and stabilize cardiac rhythms
Reverse elevations of liver enzymes (ALT, AST, ALP, LDH, CK) and inflammatory cytokines (IL-6, TNF-α, IL-1β)
In pulmonary models, BPC-157 has mitigated edema and structural lung damage, suggesting a protective role against COVID-19-associated lung injury and cytokine storm syndromes.
Neuroprotective Potential
Neurological complications of COVID-19 often result from increased blood-brain barrier permeability, neuroinflammation, and immune cell infiltration. BPC-157 has shown promise in animal studies by:
Promoting hippocampal neuron survival through vasoactive and gut-brain axis pathways
Reducing brain lesions from trauma, toxins, and metabolic insults
Counteracting encephalopathies associated with alcohol, NSAIDs, and insulin toxicity
Suppressing pro-inflammatory gene expression (NF-κB, Nos2, Cox-2)
These findings highlight its possible role in reducing encephalopathies, stroke risk, and other cerebrovascular complications associated with viral infections.
Clinical Perspective and Future Directions
BPC-157 consistently demonstrates anti-inflammatory, anti-arrhythmic, and vascular-protective properties in preclinical settings. Its ability to stabilize endothelial function, prevent thrombosis, and regulate immune responses positions it as a promising candidate for supportive care in severe viral infections, including COVID-19.
While human clinical data are lacking, the accumulated animal model evidence underscores the urgent need for controlled clinical trials to evaluate its efficacy and safety. Given its pleiotropic effects on the cardiovascular, hepatic, pulmonary, and neurological systems, BPC-157 may emerge as a valuable adjunct in the prevention of critical complications associated with viral illness.
REFERENCES
Deek SA. BPC 157 as Potential Treatment for COVID-19. Medical Hypotheses. 2021 Nov;158:110736. DOI: 10.1016/j.mehy.2021.110736. PMID: 34798584; PMCID: PMC8575535.
Józwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals, 18(2), 185. https://doi.org/10.3390/ph18020185
Sikiric, P., Seiwerth, S., Skrtic, A., Staresinic, M., Strbe, S., Vuksic, A., Sikiric, S., Bekic, D., Soldo, D., Grizelj, B., Novosel, L., Beketic Oreskovic, L., Oreskovic, I., Stupnisek, M., Boban Blagaic, A., & Dobric, I. (2025). Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Pharmaceuticals, 18(6), 928. https://doi.org/10.3390/ph18060928